We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score.
- Authors
Heon Jong Yoo; Mia Park; Won Kyo Shin; Myong Cheol Lim; SangYoon Park; Chong Woo Yoo; Kyung-Hee Kim; Kwang-Sun Suh
- Abstract
Objective: Neoadjuvant chemotherapy (NAC) has increased as first-line therapy in advanced high-grade serous ovarian carcinoma (HGSOC). However, several studies reported NACinduced platinum resistance. This study was aimed at evaluating the predictive impact of clinical factors on chemotherapy response score (CRS) and selecting patients who would respond well to NAC. Methods: This multicenter, retrospective study included patients between January 2016 and December 2021. FIGO stage III and IV HGSOC patients were eligible. Institutionally strict complete resectability criteria were used. Pathology slides were scored according to CRS criteria. Results: Among 172 HGSOC patients, 87 (50.6%) had stage IIIC disease, and 85 (49.4%) had stage IV. And 35 (20.4%) were CRS1, 103 patients were CRS2 (59.9%), and 34 patients were CRS3 (19.7%). Compared to CRS1, simultaneous metastases to distant LNs and solid organs confirmed by imaging were associated with a 75% reduction in CRS2 (odds ratio [OR]=0.25; 95% confidence interval [CI]=0.09-0.70; p=0.008). And BRCA 1/2 mutation was positively (OR=8.41; 95% CI=2.25-31.52; p=0.002) associated with CRS3 compared to CRS1. Patients with CRS3 had significantly longer progression-free survival (PFS), with median PFS of 9.8, 14.8, and 27.0 months for CRS of 1, 2, and 3, respectively (p<0.001). Overall survival (OS) was also prolonged for patients with CRS3 (p<0.001). Conclusion: Germline BRCA 1/2 mutation was a predictor of CRS3 and a good prognostic factor for survival rate. Simultaneous metastases to distant lymph nodes and solid organs were predictors of CRS1. CRS were inversely correlated with PFS and OS.
- Subjects
NEOADJUVANT chemotherapy; OVERALL survival; PROGRESSION-free survival; CANCER chemotherapy; LYMPHATIC metastasis
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p33
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2024.35.S2.P24